Here’s why the GSK share price jumped 8% today

Edward Sheldon looks at why GlaxoSmithKline plc’s (LON: GSK) share price is up significantly today.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Looking at the FTSE 100 today, healthcare giant GlaxoSmithKline (LSE: GSK) is clearly the top performer. Its shares are up 7.6% as I write, versus a rise of 0.9% for the index. According to Thomson Reuters, this is the single largest gain in the price in nine years. So what’s the driver of the price surge?

Consumer healthcare joint venture

The reason GSK shares are flying today is that the company has announced that it has reached an agreement with Pfizer to combine their consumer health businesses into a new ‘world-leading’ joint venture that will have combined sales of nearly £10bn. Glaxo will have a majority controlling equity interest of 68%, while Pfizer will have the remaining 32%.

The combination will bring together two highly-complementary portfolios of trusted consumer health brands, including GSK’s Sensodyne, Voltaren and Panadol, and Pfizer’s Advil, Centrum and Caltrate, the the JV to be the global leader in over-the-counter (OTC) products via a market share of 7.3%, according to the company.

GSK believes that the operation will be well positioned to deliver stronger sales, cash flow, and earnings growth and generate substantial cost synergies, and has said that it expects the proposed transaction to be accretive to adjusted earnings and free cash flow in the first full year after closing.

Demerger

Furthermore, given that the proposed transaction is “transformational” to the scale of its Consumer Healthcare business, Glaxo has advised that it plans to separate the JV via a demerger, and list GSK Consumer Healthcare on the stock market separately within three years of closing the transaction. “Ultimately, our goal is to create two exceptional, UK-based global companies, with appropriate capital structures, that are each well positioned to deliver improving returns to shareholders and significant benefits to patients and consumers,” said CEO Emma Walmsley.

Dividend

In other important news this morning, GSK said that it remains committed to its current dividend policy and that it expects to pay dividends of 80p per share both this year and next. The company also stated that it believes it will be well placed to deliver returns to shareholders, as well as invest in its strategic priorities going forward.

Thoughts on the deal

My thoughts on this news? I think the deal is a positive development. The joint venture means that GSK will become the OTC market leader in categories such as pain relief, digestive health, and therapeutic oral health across almost all major geographies in the world, and this should help generate significant cost savings that can be reinvested in the business.

The demerger should also create a business that is capable of generating relatively stable revenues and cash flows, which is another plus. Jefferies analyst Peter Welford points out that the consumer healthcare division could potentially support higher debt levels and as a result, this could ‘deleverage’ the pharma and vaccines business. 

As a dividend investor, I also like the news that the dividend will be maintained this year and next. At the current share price, the stock supports a yield of 5.2%.

Are the shares a ‘buy’ right now? With analysts expecting GSK to generate earnings per share of 114p for FY2018, the shares currently trade on a P/E ratio of 13.5. I think that’s a reasonable price to pay for a slice of the business.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon owns shares in GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »